Origin, Stemness, Marker and Signaling Pathway of Oral Cancer Stem Cell

Dicha Yuliadewi Rahmawati, Hernindya Dwifulqi, Ferry Sandra

Abstract


Cancer constitutes of complex heterogeneous organ-like structures with a hierarchical cell structure, and only minor phenotypic subpopulations with stem-like properties have a dual capacity to indefinitely self-renew and generate all heterogeneous cell phenotypes consisting of bulk tumor cells. Cancer stem cells (CSC) has similar properties to ordinary stem cells. It is understood that CSC is responsible for the recurrence of metastasis and drug resistance. Thus, control of CSC can provide successful therapy intervention that inhibits cancer growth and aggressive behavior. Conventional cancer therapy is realized to be insufficient for oral cancer therapy. Meanwhile, accurate targeting of OCSC has proved to be a significant challenge due to the commonality of many markers between OCSC and healthy cells. This article discusses the current understanding of oral CSC, with focus on origin, stemness, marker and signalling pathway.

Keywords: oral cancer stem cell, CSC, marker, origin, stemness, therapy


Full Text:

PDF

References


Wijaya L, Agustina D, Lizandi AO, Kartawinata MM, Sandra F. Reversing breast cancer stem cell into breast somatic stem cell. Curr Pharm Biotechnol. 2011; 12(2): 189-95, CrossRef.

Costea DE, Tsinkalovsky O, Vintermyr OK, Johannessen AC, Mackenzie IC. Cancer stem cells - New and potentially important targets for the therapy of oral squamous cell carcinoma. Oral Dis. 2006; 12(5): 443-54, CrossRef.

Aguilar-Gallardo C, Rutledge EC, Martínez-Arroyo AM, Hidalgo JJ, Domingo S, Simón C. Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. Stem Cell Rev Rep. 2012; 8(3): 994-1010, CrossRef.

Sandra F. A Brief outlook on pharmacogenetics (PGx): Focus in microRNAs (miRNAs) and cancer stem cells (CSCs). Indones J Cancer Chemoprevent. 2019; 10(1): 46-50, CrossRef.

Matsui WH. Cancer stem cell signaling pathways. Medicine. 2016; 95(1 Suppl 1): S8-19, CrossRef.

Rao CV, Mohammed A. New insights into pancreatic cancer stem cells. World J Stem Cells. 2015; 7(3): 547-55, CrossRef.

Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res. 2008; 14(13): 4085-95, CrossRef.

Shin KH, Kim RH. An updated review of oral cancer stem cells and their stemness regulation. Crit Rev Oncog. 2018; 23(3-4): 189-200, CrossRef.

Baillie R, Tan ST, Itinteang T. Cancer stem cells in oral cavity squamous cell carcinoma: A review. Front Oncol. 2017; 2(7): 112, CrossRef.

Rodini CO, Lopes NM, Lara VS, Mackenzie IC. Oral cancer stem cells – Properties and consequences. J Appl Oral Sci. 2017; 25(6): 708-15, CrossRef.

Chen YT, Chong YM, Cheng CW, Ho CL, Tsai HW, Kasten FH, et al. Identification of novel tumor markers for oral squamous cell carcinoma using glycoproteomic analysis. Clin Chim Acta. 2013; 420: 45-53, CrossRef.

Ren ZH, Zhang CP, Ji T. Expression of SOX2 in oral squamous cell carcinoma and the association with lymph node metastasis (Review). Oncol Lett. 2016; 11(3): 1973-9, CrossRef.

Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res. 2008; 14(13): 4085-95, CrossRef.

Shibata M, Hoque MO. Targeting cancer stem cells: A strategy for effective eradication of cancer. Cancers. 2019; 11(5): 732, CrossRef.

Patel SS, Shah KA, Shah MJ, Kothari KC, Rawal RM. Cancer stem cells and stemness markers in oral squamous cell carcinomas. Asian Pac J Cancer Prev. 2014; 15(20): 8549-56, CrossRef.

Peitzsch C, Nathansen J, Schniewind SI, Schwarz F, Dubrovska A. Cancer stem cells in head and neck squamous cell carcinoma: Identification, characterization and clinical implications. Cancers. 2019; 11(5): E616, CrossRef.

Kuhlmann JD, Hein L, Kurth I, Wimberger P, Dubrovska A. Targeting cancer stem cells: promises and challenges. Anticancer Agents Med Chem. 2016;16(1): 38-58, CrossRef.

Sun HR, Wang S, Yan SC, Zhang Y, Nelson PJ, Jia HL, et al. Therapeutic strategies targeting cancer stem cells and their microenvironment. Front Oncol. 2019; 9: 1104, CrossRef.

Amtha R, Gunardi I, Sandra F, Ernawati DS. Expression of CD133 in various premalignant and proliferative lesions. Dent J (Maj Ked Gigi). 2015; 48(2): 64-8, CrossRef.

Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006; 12(20 Pt 1): 6064-72, CrossRef.

Gavrielatou N, Doumas S, Economopoulou P, Foukas PG, Psyrri A. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 202; 84:101977, CrossRef.

Terrié E, Coronas V, Constantin B. Role of the calcium toolkit in cancer stem cells. Cell Calcium. 2019; 80: 141-51, CrossRef.




DOI: https://doi.org/10.21705/mcbs.v4i3.159

Indexed by:

                     

                    

                    


Cell and BioPharmaceutical Institute